Lucerno's next step for commercial device after $6M funder
Lucerno Dynamics – which recently completed its series A equity funding round, raising $6.34 million – has a commercially available device and has launched a new study with it.
The Morrisville-based company’s Class 1 device, the Lara System, is now listed with the U.S. Food and Drug Administration. The device detects and monitors infiltrations of radiotracer injections during PET/CT scans.
Consequently, Lucerno has also launched it’s Lara QI study, according to CEO Ron Lattanze. It's aimed…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Jennifer Henderson Source Type: news
More News: Biotechnology | CT Scan | Food and Drug Administration (FDA) | Funding | Health Management | PET Scan | Study